TSUMURA & CO. Logo

TSUMURA & CO.

A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.

4540 | T

Overview

Corporate Details

ISIN(s):
JP3535800001
LEI:
Country:
Japan
Address:
港区赤坂二丁目17番11号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Founded in 1893, Tsumura & Co. is a leading Japanese pharmaceutical company specializing in Kampo medicine, a traditional Japanese herbal therapy. The company's primary business is the manufacture and sale of prescription and over-the-counter (OTC) Kampo formulations, which are derived from natural substances. Its product portfolio also includes other medications and consumer items such as herbal bath salts. Tsumura manages an integrated value chain, from the procurement of raw medicinal herbs to the production of finished goods. The company is guided by a philosophy of achieving “Cho-WA” (harmony) between mind and body, blending tradition with scientific innovation to contribute to individual and societal well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 08:16
Interim Report
確認書
Japanese 8.9 KB
2025-11-11 08:14
Interim Report
半期報告書-第90期(2025/04/01-2026/03/31)
Japanese 267.3 KB
2025-09-10 07:55
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2025-08-05 07:44
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2025-07-08 07:37
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.7 KB
2025-07-01 09:20
Post-Annual General Meeting Information
臨時報告書
Japanese 27.7 KB
2025-06-24 06:22
Governance Information
内部統制報告書-第89期(2024/04/01-2025/03/31)
Japanese 25.7 KB
2025-06-24 06:21
Annual Report
有価証券報告書-第89期(2024/04/01-2025/03/31)
Japanese 3.5 MB
2025-06-24 06:21
Registration Form
確認書
Japanese 8.9 KB
2025-06-11 06:35
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 27.8 KB
2025-05-12 07:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.0 KB
2025-04-07 07:10
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2025-03-10 07:05
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.1 KB
2025-03-03 08:27
Share Issue/Capital Change
訂正臨時報告書
Japanese 30.2 KB
2025-02-20 07:30
Share Issue/Capital Change
臨時報告書
Japanese 27.8 KB

Automate Your Workflow. Get a real-time feed of all TSUMURA & CO. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TSUMURA & CO.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TSUMURA & CO. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGEN CORP Logo
Provides diagnostic tests and genomics services for food, animal, and agricultural safety.
United States of America
NEOG
NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS

Talk to a Data Expert

Have a question? We'll get back to you promptly.